deltatrials
Completed NCT00615290

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Pharmaco-epidemiological Description of the Patient Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Sponsor: Boehringer Ingelheim

Conditions HIV Infections
Interventions tipranavir
Updated 7 times since 2017 Last updated: Aug 6, 2014 Started: Jun 30, 2007 Primary completion: May 31, 2009

Listed as NCT00615290, this observational or N/A phase trial focuses on HIV Infections and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2021 — Jul 2024 [monthly]

    Completed

  5. Jun 2018 — Jan 2021 [monthly]

    Completed

▶ Show 2 earlier versions

  1. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NA → None

  2. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Agen, France, Aix-en-Provence, France, Amiens, France, Argenteuil, France, Aulnay-sous-Bois, France, Auxerre, France, Belfort, France, Besançon, France, Bondy, France, Bordeaux, France and 37 more location s